Follow-up describes the scheduled further observation or contact with trial participants after a defined event or time point. It can take place after a visit, after the end of treatment, after an adverse event or after completion of the active trial phase. The purpose and duration of the follow-up result from the protocol, the safety situation and the endpoints to be collected.
Purpose and design
A follow-up can record clinical events, laboratory values, the state of health, further treatment or trial endpoints. In the case of an adverse event, it serves to appropriately document the course, treatment, outcome and possible relationship to the trial intervention. For efficacy endpoints, it can serve the collection of events after the end of treatment. The term thus describes a process of tracking, not automatically a fixed number of days or visits.
The protocol should specify which participants are followed up, when and by what means, which data are collected and when the follow-up is completed. For safety evaluation, ICH GCP requires information on the type and duration of follow-up after adverse events. In practice, personal visits, telephone contacts, written surveys or other suitable means of contact can be used, provided they are permissible under data protection law, reasonable for the target population and regulated in the protocol or the working instructions.
Safety follow-up, data quality and participant retention
The end of trial treatment or the completion of planned data collection does not necessarily end the medical responsibility for trial-related safety issues. For adverse events, further follow-up may be necessary until an appropriate clinical condition or an endpoint defined in the protocol is reached. ICH GCP requires that adequate medical care for trial-related adverse events is ensured during and after trial participation.
Also in the event of a premature termination or an interruption of the trial, appropriate therapy and an adequate follow-up must be considered. Safety information is processed according to the reporting paths specified in the protocol. A follow-up is not an invitation to continue the trial treatment. Participants retain the right to terminate their participation. In the event of further contact, informed consent, data protection and individual circumstances must be respected.
For time-dependent endpoints, missing follow-ups can influence the interpretation of the data. Therefore, accessible contact paths, clear responsibilities and a transparent documentation of attempted contacts belong to the planning. However, participant retention must not turn into inappropriate pressure. Information about the purpose of a follow-up and the opportunity to ask questions should be comprehensible. Data necessary for the respective purpose are to be separated from data that are not required.
If data cannot be collected, the documentation must distinguish whether an appointment was missed, whether the person withdrew their participation or whether contact could not be established despite adequate attempts. These differences are relevant for the safety evaluation and the subsequent analysis. They should not be replaced by retroactive assumptions. Data management and biostatistics must consider the planned rules for missing information already prior to the analysis.
Differentiation from follow-up period and lost to follow-up
The follow-up period is the time span defined in the protocol in which observations are to be collected after a baseline event. It is a time window or analysis parameter. Follow-up, on the other hand, describes the actual measures of tracking, for example appointments, calls or the review of further medical information. A follow-up can take place within the follow-up period, but is not to be equated with it.
Lost to follow-up describes a status in which no sufficient further information is available for the planned tracking, for instance because contact can no longer be established. It is neither a synonym for the duration of the follow-up nor a diagnosis. A documented trial discontinuation or a withdrawn consent is to be distinguished from this. Respectful handling of a participant’s wish takes precedence over the attempt to close a data gap.
Relevance for clinical trials
A well-planned follow-up supports the reliable recording of safety events and endpoints without unnecessarily burdening participants. It connects protocol planning, medical care, data quality and data protection. Particularly important are unambiguous triggers, appropriate time periods, comprehensible contact attempts and a clear regulation of which information is needed after the end of treatment or after an event.
Full-service CROs such as Mediconomics support the development of follow-up procedures, safety and data management plans, training of trial sites and the monitoring of timely reporting. They coordinate clinical operations, pharmacovigilance, data management and biostatistics so that follow-up data are comprehensibly collected, protected and usable for the intended analyses.
Frequently Asked Questions (FAQ)
Does a follow-up always start only after the end of treatment?
No. Follow-up can take place after an adverse event, after a visit or after the end of treatment. The specific trigger and the duration should be defined in the protocol or in the safety procedures.
Is lost to follow-up the same as a withdrawal of consent?
No. Lost to follow-up describes a lack of reachability or missing information for tracking. A withdrawal is a conscious decision of the person and must be respected and documented as such.
Must a safety follow-up still take place after the end of the trial?
If this is required for an adverse event, a protocolled safety issue or adequate medical care, tracking may be necessary after the end of the active trial phase.
Regulatory references
- ICH E6(R3) Good Clinical Practice — protection of participants, safety follow-up and availability of trial-related data.
- ICH E8(R1) General Considerations for Clinical Studies — clear trial objectives and quality-relevant planning.
- Regulation (EU) No 536/2014 on clinical trials — safety monitoring and protection of participants.
- Declaration of Helsinki of the World Medical Association — continuous protection and respect for research participants.